

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Emapalumab for treating primary haemophagocytic
lymphohistiocytosis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Not all HLH patients may be appropriate candidates for haematopoietic stem cell transplantation (HSCT) due to the extent of tissue damage, lack of suitable donor (particularly the availability of donors in minority ethnic groups), etc.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

If the availability of suitable stem-cell donors is lower in specific groups, or for people where a HSCT is unsuitable, the committee should give consideration to the effectiveness of current alternative treatments and should consider whether its recommendations disadvantage such groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Yes – the ‘Other considerations’ section of the scope was amended so if evidence allows, consideration may be given to subgroups based on people for whom a HSCT is unsuitable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
--

No

Approved by Associate Director (name): Jasdeep Hayre

Date: 06/08/2019